Literature DB >> 2957234

The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer.

P J Finan, E M Chisholm, L Woodhouse, G R Giles.   

Abstract

To assess the relationship between the plasma pharmacokinetics of 5-Fluorouracil (5-FU) and the levels of intracellular 5-FU metabolites, we have studied eight patients presenting with primary carcinomas of the colon and rectum. Serum 5-FU levels and fluorinated metabolites within normal and malignant tissue were estimated using chromatographic methods. An analysis of the total fluorinated products against plasma halflife, plasma clearance and maximum plasma concentration failed to demonstrate any significant correlation. Furthermore the differing levels of 5-FU metabolites in normal and malignant tissue could not be correlated with the pharmacokinetic parameters studied. It is concluded that the cellular levels of active 5-FU metabolites reflect local cellular activity rather than the handling of the drug in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957234

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Comparison of 5-fluorouracil anabolite levels after intravenous bolus and continuous infusion.

Authors:  T A Stein; B Bailey; G P Burns
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.

Authors:  G W Visser; G C Gorree; G J Peters; J D Herscheid
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 4.  Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.

Authors:  P Chrisp; D McTavish
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

5.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Authors:  M Barberi-Heyob; B Weber; J L Merlin; C Dittrich; E A de Bruijn; E Luporsi; F Guillemin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours.

Authors:  T Dresselaers; J Theys; S Nuyts; B Wouters; E de Bruijn; J Anné; P Lambin; P Van Hecke; W Landuyt
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.